The IP-protected CBD intermediate offers superior functionality that enables higher drug loading compared to currently commercially available products, paving the way for oral dosage forms with improved bioavailability. This will enable the development of more convenient and more patient-friendly dosage forms such as tablets, including orally disintegrating tablets (ODTs) or chewables, making CBtru a significant advance in cannabinoid innovation with the ability to transform CBD-based therapies.
Pioneering a new frontier in CBD drug development
Existing CBD-based medicines have limited oral bioavailability (up to 6% in humans) and therefore efficacy, due to the poor solubility and absorption of the cannabinoid molecules. Consequently, large doses of CBD are needed for therapeutic efficacy and require administration via oil-based oral solutions, which can be uncomfortable and unpleasant for patients. dsm-firmench says its advanced CBD drug intermediate formulation aims to address this challenge. It enables higher active loading, improved stability and optimized pharmacokinetic performance, enabling the creation of more bioavailable and more patient-tailored dosage forms.
A molecule that has immense therapeutic potential
“We are committed to improving overall patient health by unlocking new treatment possibilities and improving product acceptance and compliance. That’s why we’ve invested in CBD, a molecule that has immense therapeutic potential, as evidenced by promising research and a changing favorable regulatory environment,” said Athanasia Kanli, global pharmaceutical business development manager at dsm-firmenich.
“Until now, the application of CBD has been limited to petroleum-based delivery systems, mainly due to its low bioavailability and physical and chemical instability. This inspired us to introduce CBtru to the rapidly expanding cannabinoid market. With its advanced functionality, CBtru can facilitate the development of faster-acting, more effective and patient-friendly treatments, representing a new era in cannabinoid-based medicines.
The result of two years of focused research
dsm-firmench’s new intermediate CBD medicine is the result of two years of focused research. During this period, the company’s technical team rigorously evaluated more than 200 prototypes and multiple drug delivery technologies to identify a superior performing CBD solution. Moving forward, dsm-firmench looks forward to establishing long-term strategic partnerships to investigate new therapeutic applications leveraging its trial-ready CBtru formulation.
More than CBtru
Together with Brains Bioceutical, a manufacturer of high quality pharmaceutical grade cannabinoids, dsm-firmenich offers an end-to-end innovation platform designed to support early stage cannabinoid drug development and realize the potential of based formulations in CBD. Its capabilities include cutting-edge formulation expertise, a global network of regulatory specialists and expertise in preclinical and clinical studies. The company also has the ability to offer customized solutions depending on the therapeutic area and the goal of drug delivery.